Ativan Tapering Guide
lorazepam
Boxed Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Risks of abuse, misuse, and addiction, which can lead to overdose and death. Physical dependence and life-threatening withdrawal reactions.
Overview
Lorazepam is an intermediate-acting benzodiazepine approved for anxiety disorders and as a pre-anesthetic. It has no active metabolites and is metabolized by glucuronidation, making it preferred in patients with hepatic impairment or in the elderly.
0.5mg, 1mg, 2mg
Tablets: 0.5mg, 1mg, 2mg; Oral concentrate: 2mg/mL; Injection: 2mg/mL, 4mg/mL
Category D (positive evidence of risk)
Mechanism of Action
Positive allosteric modulator at GABA-A receptors. Binds to the benzodiazepine site and enhances GABA-mediated chloride conductance, producing anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
Taper Notes
Intermediate half-life (10–20 hours) and absence of CYP-mediated metabolism (glucuronidation only) make lorazepam useful in hepatic impairment. Diazepam crossover often improves taper smoothness; oral concentrate (2 mg/mL) supports precise sub-tablet dosing.
Maudsley Deprescribing Guidance
Ashton-protocol diazepam crossover is widely used given lorazepam's shorter half-life. Lorazepam 1 mg ≈ diazepam 10 mg. Abrupt discontinuation carries seizure risk after chronic use.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Crossover to diazepam (optional) | 2-4 weeks | Per Ashton protocol: lorazepam 1 mg ≈ diazepam 10 mg. Crossover smooths plasma kinetics for the remainder of the taper. |
| Initial reductions | 2-4 weeks per step | Reduce by ~5–10% per step using oral concentrate (2 mg/mL) for precision. Hold at each dose until symptoms stabilize. |
| Middle reductions | 2-4 months | Lorazepam's shorter half-life favors TID/QID dosing splits to minimize interdose fluctuations during reductions. |
| Final reductions | 2-4 months | Oral concentrate supports the smallest increments. Extend hold periods to 4+ weeks if symptoms emerge in the terminal phase. |
Withdrawal Timeline
12-24 hours after reduction (faster than Klonopin due to shorter half-life)
3-7 days
2-6 weeks for acute symptoms
Anxiety rebound, insomnia, and depersonalization may persist 3-12 months. Shorter half-life than Klonopin means somewhat faster acute resolution but protracted symptoms are similar.
Clinical Pearls
Practical considerations for clinicians supervising Ativan tapers.
- 1Oral concentrate (2 mg/mL) is the preferred dosing tool for sub-tablet increments and reliable sub-mg dosing.
- 2Lorazepam's glucuronidation-only metabolism means minimal CYP interactions — a clinical advantage in polypharmacy and hepatic impairment compared to other benzodiazepines.
- 3Splitting the daily dose to TID or QID smooths plasma curves and reduces interdose withdrawal during reductions.
- 4Diazepam crossover (1 mg lorazepam ≈ 10 mg diazepam) is often worth the initial adjustment period for patients facing prolonged tapers; the smoother kinetics simplify the subsequent reductions.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Opioids — FDA boxed warning: concurrent use increases risk of profound sedation, respiratory depression, coma, and death
- CNS depressants (alcohol, barbiturates, other sedatives) — additive respiratory depression
- Probenecid and valproate may increase lorazepam levels (inhibit glucuronidation)
Food Interactions
- Food may slow absorption rate but does not reduce total bioavailability
- Avoid alcohol (additive CNS and respiratory depression, potentially fatal)
Contraindications
- Acute narrow-angle glaucoma
- Known hypersensitivity to lorazepam or other benzodiazepines
- Intra-arterial injection (parenteral formulation)
Toxicity
CNS and respiratory depression, especially with opioids or alcohol. Physical dependence with chronic use. Abrupt discontinuation can cause seizures, psychosis, and death.
External References
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~90%. Tmax ~2 hours. Food may slow absorption but does not reduce bioavailability.
~1.3 L/kg
Hepatic via glucuronidation (UGT) to the inactive lorazepam glucuronide. Does NOT undergo CYP-mediated oxidative metabolism, making it preferred in hepatic impairment.
Renal (~88% as glucuronide conjugate). Less than 1% excreted unchanged in urine.
~85%
~1.1 mL/min/kg
Build Ativan taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds